Christine Kay, MD
Ophthalmology · Gainesville, FLNPI 1881898419
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Spark Therapeutics, Inc. accounts for 64.7% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $51,276 and has fallen 95.1% since, to $2,526 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $814.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Spark Therapeutics, Inc.$87K
- Janssen Global Services, LLC$20K
- Biogen$7K
- Sanofi US Services Inc.$4K
- F. Hoffmann-la Roche AG$4K
- Cortigent Inc$3K
- plus $9K from 19 others
Across 300 payments — averaging $4824.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1M
- Biogen$270K
- Novartis$54K
- Sanofi US Services Inc.$49K
- AbbVie$20K
- Astellas Pharma Global Development$18K
- plus $13K from 3 others
What the payments were for
- Consulting fees$39,63630%
- Speaking & faculty fees$80,35060%
- Travel & lodging$10,7818%
- Food & beverage$3,5723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Spark Therapeutics, Inc. | 55 | $86,948 |
| Janssen Global Services, LLC | 25 | $20,224 |
| Biogen | 1 | $7,200 |
| Sanofi US Services Inc. | 6 | $4,318 |
| F. Hoffmann-la Roche AG | 1 | $3,925 |
| Cortigent Inc | 5 | $3,100 |
| Novartis Pharma AG | 1 | $2,800 |
| Johnson & Johnson | 1 | $1,815 |
| PTC Therapeutics, Inc. | 1 | $800 |
| Alnylam Pharmaceuticals Inc. | 1 | $630 |
| Vertex | 1 | $483 |
| Regeneron Healthcare Solutions, Inc. | 14 | $418 |
| Genentech USA, Inc. | 16 | $405 |
| Astellas Pharma US Inc | 6 | $253 |
| AbbVie(2 entities) | 4 | $180 |
| Boston Scientific | 9 | $167 |
| Kala Pharmaceuticals, Inc. | 1 | $162 |
| Amgen | 1 | $123 |
| Mallinckrodt Enterprises LLC | 1 | $121 |
| Novo Nordisk | 6 | $99 |
| Apellis Pharmaceuticals, Inc. | 4 | $84 |
| Bausch & Lomb Americas Inc. | 2 | $40 |
| Eyepoint US, Inc. | 1 | $16 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| Halozyme Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,340 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 12 | $4,224 |
| Prednisolone Acetate | 65 | $3,484 |
| Difluprednate | 31 | $3,427 |
| Loteprednol Etabonate | 11 | $2,124 |
| Ketorolac Tromethamine | 39 | $1,186 |
| Dorzolamide Hcl | 58 | $806 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $406 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $303 |
| Timolol Maleate | 32 | $296 |
| ErythromycinErythromycin Base | 20 | $135 |
| Latanoprost | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $2,12411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Gainesville
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.